Edwards Lifesciences Corporation EW
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.72B | 1.74B | 1.65B | 1.57B | 1.55B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.72B | 1.74B | 1.65B | 1.57B | 1.55B |
| Cost of Revenue | 369.20M | 392.40M | 362.60M | 343.00M | 345.20M |
| Gross Profit | 1.35B | 1.35B | 1.29B | 1.23B | 1.21B |
| SG&A Expenses | 560.90M | 561.20M | 522.20M | 601.20M | 514.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -13.30M | -11.00M | -14.20M | -14.30M | -12.50M |
| Total Operating Expenses | 1.20B | 1.22B | 1.13B | 1.20B | 1.13B |
| Operating Income | 517.30M | 519.50M | 514.70M | 372.00M | 425.10M |
| Income Before Tax | 363.20M | 519.80M | 459.00M | 90.40M | 348.40M |
| Income Tax Expenses | 61.80M | 278.40M | 78.30M | 26.20M | 56.10M |
| Earnings from Continuing Operations | 301.40M | 241.40M | 380.70M | 64.20M | 292.30M |
| Earnings from Discontinued Operations | -- | -- | -- | 27.00M | -2.00M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 6.10M | 500.00K | -- | 0.00 | 800.00K |
| Net Income | 307.50M | 241.90M | 380.70M | 91.20M | 291.10M |
| EBIT | 517.30M | 519.50M | 514.70M | 372.00M | 425.10M |
| EBITDA | 562.20M | 562.20M | 555.60M | 414.70M | 464.30M |
| EPS Basic | 0.53 | 0.42 | 0.66 | 0.16 | 0.50 |
| Normalized Basic EPS | 0.62 | 0.56 | 0.65 | 0.50 | 0.48 |
| EPS Diluted | 0.53 | 0.42 | 0.66 | 0.15 | 0.50 |
| Normalized Diluted EPS | 0.62 | 0.55 | 0.65 | 0.50 | 0.48 |
| Average Basic Shares Outstanding | 576.30M | 576.40M | 579.20M | 580.40M | 584.70M |
| Average Diluted Shares Outstanding | 577.60M | 577.60M | 580.70M | 581.80M | 585.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |